CRYSTOLITE PHARMACEUTICALS
Pharmaceutical manufacturer · Islamabad · Pakistan
Islamabad-area pharmaceutical manufacturer established in 2004, manufacturing and marketing pharmaceutical and healthcare products for domestic and export markets.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Pharmaceutical manufacturer
- Address
- Plot #1 & 2, Street S-2, National Industrial Zone, Rawat, Islamabad, Pakistan
- Website
- crystolite.com.pk ↗
- Phone
- +92 342 0022555
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Adnast | Anastrozole | 1 mg | Tablet | 28’s | 088459 | PKR 9,550.61 | PKR 341.09/tablet | Near median |
| Anlev | Levofloxacin | 500 mg | Tablet | 10’s | 077610 | PKR 829.80 | PKR 82.98/tablet | Near median |
| Anlev | Levofloxacin | 250 mg | Tablet | 1x10’s | 078019 | PKR 498.67 | PKR 49.87/tablet | Near median |
| Asitor-C | Amlodipine | 10 mg | Tablet | 20’s | 082448 | PKR 627.25 | PKR 31.36/tablet | 84% above median |
| Asitor-C 10 | Amlodipine + Atorvastatin | 10 mg + 10 mg | Tablet | 14’s | 082449 | PKR 503.72 | PKR 35.98/tablet | 72% above median |
| Asset | Acitretin | 25 mg | Capsule | 30’s | 077615 | PKR 2,546.20 | PKR 84.87/capsule | 6% below median |
| Bptin-H | Amlodipine + Valsartan + Hydrochlorothiazide | 5 mg + 12.5 mg + 160 mg | Tablet | 14’s | 101830 | PKR 233.24 | PKR 16.66/tablet | 50% above median |
| Bptin-H | Amlodipine + Valsartan + Hydrochlorothiazide | 10 mg + 25 mg + 160 mg | Tablet | 14’s | 101831 | PKR 255.72 | PKR 18.27/tablet | No comparator |
| Bptin-H | Amlodipine + Valsartan + Hydrochlorothiazide | 10 mg + 25 mg + 320 mg | Tablet | 14’s | 101832 | PKR 393.41 | PKR 28.10/tablet | No comparator |
| Bptin-H | Amlodipine + Valsartan + Hydrochlorothiazide | 5 mg + 25 mg + 160 mg | Tablet | 14’s | 101833 | PKR 238.85 | PKR 17.06/tablet | No comparator |
| Bptin10 | Amlodipine + Valsartan | 10 mg + 160 mg | Tablet | 14’s | 082431 | PKR 751.14 | PKR 53.65/tablet | 15% above median |
| Bptin5 | Amlodipine + Valsartan | 5 mg + 160 mg | Tablet | 14’s | 082430 | PKR 640.13 | PKR 45.72/tablet | 9% above median |
| Bptin5 | Amlodipine + Valsartan | 5 mg + 80 mg | Tablet | 14’s | 082432 | PKR 447.73 | PKR 31.98/tablet | 8% above median |
| C-Val Plus | Hydrochlorothiazide | 80 mg | Tablet | 28’s | 082436 | PKR 677.14 | PKR 24.18/tablet | 53% below median |
| C-Val Plus | Valsartan + Hydrochlorothiazide | 12.5 mg + 160 mg | Tablet | 14’s | 082437 | PKR 547.63 | PKR 39.12/tablet | No comparator |
| C-Val Plus 25 | Valsartan + Hydrochlorothiazide | 25 mg + 160 mg | Tablet | 14’s | 082438 | PKR 573.53 | PKR 40.97/tablet | No comparator |
| Calpsor | Calcipotriol | 50 mcg/mL | Lotion | 30ml | 077719 | PKR 1,519.57 | PKR 50.65/mL | No comparator |
| Calpsor-B | Calcipotriol + Betamethasone | 50 mcg/mL + 500 mcg/mL | Lotion | 30ml | 077720 | PKR 1,502.41 | PKR 50.08/mL | No comparator |
| Canix | Clotrimazole | 10 mg/mL | Lotion | 30ml | 077643 | PKR 63.06 | PKR 2.10/mL | 6% above median |
| Canix | Clotrimazole | 10 mg/mL (1%) | Lotion | 60ml | 077643 | PKR 119.83 | PKR 2.00/mL | No comparator |
| Canix | Clotrimazole | 1% | Cream | 15gm | 082321 | PKR 95.74 | PKR 6.38/g | 13% above median |
| Canix W/W | Clotrimazole | 1 % | Cream | 10gm | 082321 | PKR 63.82 | PKR 6.38/g | Near median |
| Canix-H | Hydrocortisone | 10 mg | Cream | 10gm | 077636 | PKR 114.05 | PKR 11.41/g | No comparator |
| Canix-H | Clotrimazole + Hydrocortisone | 10 mg + 10 mg | Cream | 15gm | 077636 | PKR 171.08 | PKR 11.41/g | Near median |
| Canix-H | Hydrocortisone | 10 mg/g | Cream | 20gm | 077636 | PKR 210.42 | PKR 10.52/g | No comparator |
| Cifram | Ciprofloxacin | 250 mg | Tablet | 10’s | 077612 | PKR 259.32 | PKR 25.93/tablet | Near median |
| Cifram | Ciprofloxacin | 500 mg | Tablet | 10’s | 077613 | PKR 428.86 | PKR 42.89/tablet | Near median |
| Cimox | Moxifloxacin | 400 mg | Tablet | 5’s | 077608 | PKR 947.48 | PKR 189.50/tablet | Near median |
| Clindaben | Clindamycin | 10 mg | Gel | 10gm | 093396 | PKR 448.44 | PKR 44.84/g | 22% above median |
| Cosalic | Salicylic acid + Coal tar + Hydrocortisone | 3% + 3% + 1% | Lotion | 60ml | 077653 | PKR 613.95 | PKR 10.23/mL | Near median |
| Cosalic | Salicylic acid + Coal tar + Hydrocortisone | 3% + 3% + 1% | Lotion | 30ml | 077653 | PKR 323.13 | PKR 10.77/mL | 5% above median |
| Crystra | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120’s | 102659 | PKR 12,331.99 | PKR 102.77/tablet | 7% above median |
| Crysvir | Oseltamivir | 75 mg | Capsule | 10’s | 102660 | PKR 1,384.94 | PKR 138.49/capsule | 15% above median |
| Daclavir | Daclatasvir | 30 mg | Tablet | 28’s | 085241 | PKR 5,549.24 | PKR 198.19/tablet | Near median |
| Daclavir | Daclatasvir | 60 mg | Tablet | 28’s | 085242 | PKR 9,079.86 | PKR 324.28/tablet | Near median |
| Daskil | Terbinafine | 1 % | Cream | 10gm | 077624 | PKR 294.42 | PKR 29.44/g | Near median |
| Differin | Adapalene + Benzoyl peroxide | 0.1% + 2.5% | Gel | 15gm | 077633 | PKR 324.53 | PKR 21.64/g | No comparator |
| Differin | Benzoyl peroxide | 0.1% | Gel | 30gm | 077633 | PKR 584.93 | PKR 19.50/g | No comparator |
| Dopiral | Clopidogrel | 75 mg | Tablet | 10’s | 082450 | PKR 279.26 | PKR 27.93/tablet | Near median |
| Ecozone | Cefotaxime | 250 mg | IV/IM injection | 1’s | 089548 | PKR 113.21 | PKR 113.21/vial/unit | 7% above median |
| Ecozone | Cefotaxime | 500 mg | IV/IM injection | 1’s | 089549 | PKR 170.62 | PKR 170.62/vial/unit | 7% above median |
| Ecozone | Cefotaxime | 1 g | IV/IM injection | 1’s | 089550 | PKR 306.88 | PKR 306.88/vial/unit | Near median |
| Entaliv-b | Entecavir | 0.5 mg | Tablet | 3x10’s | 090023 | PKR 12,965.53 | PKR 432.18/tablet | 21% above median |
| Epiwin | Sodium valproate | 250 mg/5 mL | Syrup | 60ml | 091753 | PKR 97.08 | PKR 1.62/mL | 12% below median |
| Epiwin | Sodium valproate | 250 mg/5 mL | Syrup | 120ml | 091753 | PKR 220.04 | PKR 1.83/mL | Near median |
| Fermin | Iron polymaltose complex | 50 mg/5 mL | Syrup | 60ml | 082427 | PKR 139.62 | PKR 2.33/mL | Near median |
| Fermin | Iron polymaltose complex | 50 mg/5 mL | Syrup | 120ml | 082427 | PKR 257.59 | PKR 2.15/mL | 8% below median |
| Fermin | Elemental Iron | 100 mg | Tablet | 20’s | 086260 | PKR 339.09 | PKR 16.95/tablet | 24% above median |
| Fermin Plus | Iron polymaltose complex + Folic acid | 50 mg elemental iron + 0.35 mg folic acid/5 mL | Syrup | 120ml | 082424 | PKR 257.59 | PKR 2.15/mL | Near median |
| Fermin Plus | Iron + Folic acid | 0.35 mg/5 mL + 0.35 mg/5 mL | Syrup | 60ml | 082424 | PKR 139.62 | PKR 2.33/mL | No comparator |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.